anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of ALTUVIIIO has been evaluated in 159 previously treated patients (PTPs) (134 adults and 25 adolescents) with severe Hemophilia A (<1% endogenous FVIII activity or a genetic mutation consistent with severe Hemophilia A) who received at least one dose of ALTUVIIIO for either routine prophylaxis, on-demand treatment of bleeding episodes or perioperative management. A total of 152 (96%) subjects achieved at least 25 exposure days and 115 (72%) subjects achieved at least 50 exposure days with a median of 53.0 (range 2–63) for both exposure days and injections per subject. Overall exposure was monitored for a total of 151.5 subject-years.

In the pediatric study, the safety of ALTUVIIIO was evaluated in 74 male PTPs <12 years of age with severe hemophilia A who received at least one dose of ALTUVIIIO. Sixty-six (89.2%) subjects achieved at least 50 exposure days with a median of 53.0 (range 3–72).

Adverse events were monitored for a total of 210.7 subject-years in 2 completed clinical studies in PTPs. Adverse drug reactions (ADRs) (summarized in Table 3) were reported in 79 (33.9%) of the 233 subjects treated with routine prophylaxis or on-demand therapy. The most common ADRs (>10%) in adults and adolescents were headache (20.1%) and arthralgia (16.4%). In children below 12 years, pyrexia (12.2%) was the most common ADR (>10%). In the studies, no inhibitors to FVIII were detected and no ADRs of anaphylaxis were reported.

Thromboembolic events occurred in 1% (3/261) of subjects in the long-term safety extension study; these three subjects had pre-existing risk factors. 

Immunogenicity

All subjects were monitored for neutralizing antibodies (inhibitors) to Factor VIII in the clinical program. No subjects developed neutralizing antibodies to Factor VIII [see Immunogenicity (12.6)].
Phase 2a expansion cohort for patients with NSCLC. Patients will be treated at the maximum tolerated dose discovered in phase I.
Climate change and global warming are a global public health problem. This situation, which affects all masses, also deeply affects human life. Future nurses need to have high awareness of this situation and educate and inform the society about this situation. Nurse students' environmental attitudes, knowledge and behavior towards the environment need to be increased. The aim of this research is to determine the effect of global warming and climate change-based education given to nursing students on their environmental attitudes.The research was planned as a randomized controlled experimental. According to the posthoc power analysis, it was determined that the type one error amount was 0.05 with a medium effect size and the power of the study was 94% when 110 participants were taken. The data were included from the 2nd, 3rd and 4th grades of a nursing faculty in eastern Turkey. Assignments were made to experimental and control groups by randomization. Personal information form and environmental attitude scale were used to collect data.
A standardized extract of cultured Lentinula edodes mycelia (ECLM, AHCC®) has been shown to have beneficial effects on organ metabolism. ECLM has been indicated to have liver protective properties by suppressing inflammatory responses. The pathogenesis of hepatic ischemia-reperfusion injury is thought to involve the induction of inflammatory mediators. However, whether ECLM affects inflammatory mediators caused by warm hepatic ischemia-reperfusion injury and partial hepatectomy (HIRI+PH) has not been clarified. In this study, we evaluated the protective effects of ECLM against liver damage caused by HIRI+PH. Rats were fed a normal diet (HIRI+PH) or a normal diet with 2% ECLM (HIRI+PH and ECLM) for ten days, then the liver and duodenal ligament were clamped and subjected to 15 min of hepatic ischemia. After 70% hepatectomy, the inflow occlusion was released, and liver and blood samples were collected at 3, 6, and 24 h. The effect of ECLM on mortality induced by 30 min of ischemia and hepatectomy was evaluated. The results showed that ECLM attenuated pathological liver damage, including apoptosis, in the rats treated with HIRI+PH, and decreased serum aminotransferase activity; ECLM decreased mRNA levels of the inflammation-related genes inducible nitric oxide synthase and C-X-C motif chemokine ligand 1, and increased mRNA levels of interleukin 10, an anti-inflammatory cytokine; ECLM increased hepatocyte growth factor mRNA levels and Ki-67 labeled nuclei in the liver at 24 h; ECLM significantly reduced HIRI+PH-induced mortality. In conclusion, ECLM may prevent HIRI+PH-induced liver injury in part by suppressing various inflammatory responses and promoting liver regeneration.
Intravenous amiodarone has been reported to produce negative inotropic and vasodilatory effects in animals and humans. In clinical studies of patients with refractory VF or hemodynamically unstable VT, treatment-emergent, drug-related hypotension occurred in 288 of 1836 patients (16%) treated with intravenous amiodarone. No correlations were seen between the baseline ejection fraction and the occurrence of clinically significant hypotension during infusion of intravenous amiodarone.

No data are available on the activity of DEA in humans, but in animals, it has significant electrophysiologic and antiarrhythmic effects generally similar to amiodarone itself. DEA's precise role and contribution to the antiarrhythmic activity of oral amiodarone are not certain. The development of maximal ventricular class III effects after oral amiodarone administration in humans correlates more closely with DEA accumulation over time than with amiodarone accumulation. On the other hand, after intravenous amiodarone administration, there is evidence of activity well before significant concentrations of DEA are attained [see Clinical Trials (14)].
Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
PROBLEM TO BE SOLVED: To obtain a new compound, having two actions of inhibiting actions on a lipoxygenase and inhibiting actions on a thromboxane synthase and useful for treating and mitigating allergic diseases, etc. SOLUTION: This compound is represented by formula I (one of R1 to R3 is 3-pyridyl, etc., and the others are H, a 1-8C alkyl, etc.; R4 is H or a lower alkyl; R5 is H, a lower alkyl, etc.; A is a bond, a 1-20C alkylene, etc.), e.g. N-hydroxyl-N-[[3-pyridylmethyl)indolyl]]methylurea. The compound represented by formula I is obtained by reacting an alcohol represented by formula II (Q is represented by formula III) with N,O-bis(tert-butoxycarbonyl)hydroxylamine under conditions of the Mitsunobu reaction, providing a compound represented by formula IV in which the N and O are protected, then hydrolyzing the resultant compound with an acid, affording a compound represented by formula V and further reacting the compound represented by formula V with trimethylsilyl isocyanate.
Intravenous polymyxin B will be started on a standard dose of 25,000 Units (U)/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 million units (MU) 8 hourly for 5 days will be prescribed.
PURPOSE:To provide a new itaconic acid derivative useful as a medicine, especially having a hypoglycemic activity and useful as a diabete. CONSTITUTION:An itaconic acid derivative of formula I (R is H, 1-6C alkyl; A is halogen or phenyl, heterocyclic or 3-8C cycloalkyl which may be substituted with a 1-4C alkyl or 1-4C alkoxy; B is monocyclic amino which, if necessary, has an unsubstituted bond in the ring and which may be substituted with a 1-6C alkyl or aryl) and its salt, e.g. (E)-2-benzilidene-3-(1-pyrrolidinylcarbonyl) propionic acid. The compound of formula I is obtained e.g. by reacting itaconic anhydride with an amine compound of formula III and, if necessary, esterifying the reaction product. An ester compound having the 1-6C alkyl as the R among the compound of formula I is obtained by reacting the reactive functional derivative of an itaconic acid monoester compound of formula IV (R<4> us 1-6C alkyl) with the compound of formula III.
Major late life depression (LLD) is an important health problem with a large and growing number of affected individuals. A significant subset of patients with LLD, particularly those with vascular depression, have abnormalities in certain parts of the brain that are evident on MRI scans and may be associated with poor acute and long-term response to antidepressant treatment. Studies have also indicated that LLD patients frequently have frontal lobe dysfunction. A longitudinal study with the antidepressant nortriptyline has demonstrated that frontal lobe dysfunction is associated with poor acute response and a greater risk for recurrence of LLD. However, it is not known if this finding applies to other antidepressants. This study will be the first clinical trial to simultaneously test the effects of specific brain and psychological factors on course of response, remission rate, and other measures of health outcomes in people with LLD.

Participants are treated with sertraline for 12 weeks. During this period, participants undergo cognitive testing, MRI, electrocardiogram (EKG), and laboratory tests. Study visits occur every 2 weeks.
This is a non-blinded, non-randomized controlled pilot study with patients who will be followed during their coronary angiography procedure and with no follow-up. Patients will be recruited from the coronary angiography patient pool of the American Hospital of Paris and assigned to one of 2 groups in a non-randomized manner. It is expected to enroll around 100 patients and this is estimated to be obtained in a period of 2 months approximately. Patients will be placed in the control group, without music intervention, or assigned to the music group. Assignment will be done in this manner due to limited availability of the hardware and software to the investigation team. Patients in both groups will be matched based on age, sex, weight, height, American Society of Anesthesiology (ASA) score, and prior medical history, including diabetes, hypertension, chronic kidney disease and stroke. Each patient will receive a standardized sedation in the traditional manner and at the discretion of the investigator to reach Bispectral index (BIS) score below 90 and sedation score ≤ 1. The primary study end points will be the consumptions in analgesics and hypnotics. Secondary study end points will be pain and anxiety scores as measured the Numeric Rating Scale (NRS), the Visual Analog Scale (VAS) and the Amsterdam Preoperative Anxiety and Information Scale (APAIS).
BACKGROUND: Artificial joint replacement has become one of the most effective means for the clinical treatment of senile degenerative end-stage bone and joint diseases. All complications were directly or indirectly related to bleeding, and low body temperature can lead to bleeding, which have been a conceren in rthroplasty for elderly patients.
METHODS: The computer retrieves eight databases, including Cochrane Library, PubMed, EMbase, Web of Science, CNKI, China Biomedical Literature Database (CBM), VIP and WanFang, to obtain controlled trials at home and abroad on the effects of body temperature protection on intraoperative bleeding in elderly patients undergoing arthroplasty. The search term is "temperature", "bleeding," and "arthroplasty". The search time was from the establishment of the library until February 2022. The literature screening results were obtained by reading the full text, and the process was completed independently by 2 researchers.After a rigorous literature quality evaluation, data analysis was performed using RevMan 5.3 software.
RESULTS: 9 studies were ultimately included in this meta-analysis. 8 studies reported the blood loss of the test group and the control group. Meta-analysis showed that the blood loss of the test group was significantly lower (SMD: -45.09; 95% Cl: -67.76, -22.43; P < .01) than the control group. 44 studies showed that the Number of blood transfusions of the experimental group was significantly lower than the control group (OR:0.60; 95% Cl: 0.39,0.92; P = .01). 3 studies showed that the intraoperative temperature of the experimental group was significantly higher than the control group (SMD:0.60; 95% Cl: 0.20,0.99; P = .003). 4 studies showed that the postoperative temperature of the test group was significantly higher than the control group (SMD: 0.83; 95% Cl: 0.47,1.19; P < .01). 4 studies showed that the shiver incidence of the experimental group was significantly lower than the control group (OR:0.29; 95% Cl: 0.19,0.46; P < .01).
CONCLUSION: The results of this study suggest that active body temperature protection may be effective on intraoperative bleeding in elderly patients undergoing arthroplasty, as evidenced by blood loss, number of blood transfusions, intraoperative temperature, postoperative temperature, shiver incidence, length of hospital stay.
Approximately one-quarter of strokes occur in individuals with prior stroke. Despite the advancement in secondary stroke prevention, the long-term risk of recurrent stroke has remained unchanged. The objective of this study was to identify metabolite risk markers that are associated with recurrent stroke. We performed targeted metabolomic profiling of 162 metabolites by liquid chromatography-tandem mass spectrometry in baseline plasma in a stroke case-cohort study nested within the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, an observational cohort study of 30,239 individuals aged 45 and older enrolled in 2003-2007. Weighted Cox proportional hazard models were used to identify metabolites that had a differential effect on first-time versus recurrent stroke using an interaction term between metabolite and prior stroke at baseline (yes or no). The study included 1391 incident stroke cases identified during 7.1 ± 4.5 years of follow-up and 1050 participants in the random cohort sample. Among 162 metabolites, 13 candidates had a metabolite-by-prior stroke interaction at a p-value <0.05, with one metabolite, acetylglutamine, surpassing the Bonferroni adjusted p-value threshold (p for interaction = 5.78 × 10-5). In an adjusted model that included traditional stroke risk factors, acetylglutamine was associated with recurrent stroke (HR = 2.27 per SD increment, 95% CI = 1.60-3.20, p = 3.52 × 10-6) but not with first-time stroke (HR = 0.96 per SD increment, 95% CI = 0.87-1.06, p = 0.44). Acetylglutamine was associated with recurrent stroke but not first-time stroke, independent of traditional stroke risk factors. Future studies are warranted to elucidate the pathogenesis of acetylglutamine and recurrent stroke risk.
Methods and systems for detecting an autism state are disclosed. A plurality of data arrays are received, each including a plurality of values. Each of the plurality of values represent a concentration of a different metabolite. A score for each of the plurality of data arrays is calculated based on a relationship between the plurality of values of each of the respective plurality of data arrays. The score for each of the plurality of data arrays is classified into an autism class and a neurotypical class. A test score for a test data array is calculated based on a relationship between the plurality of test values and can then be grouped into one of the autism class and the neurotypical class. The system thus can use biomarkers identified in a metabolic pathway, such as abnormalities in folate-dependent one-carbon metabolism (FOCM) and transsulfuration (TS), to identify patients with a high likelihood of having autism.
Antibody-secreting cells (ASCs) produce immunoglobulin (Ig) G and IgE autoantibodies in secondary lymphoid organs. Evidence also suggests their existence in the skin in various chronic inflammatory conditions, and in association with CXCL12 and CXCL13, they regulate the recruitment/survival of ASCs and germinal center formation to generate ASCs, respectively. However, the presence of IgG and IgE in bullous pemphigoid (BP) lesions needs to be addressed. Here, we aimed to analyse BP skin for the presence of IgG and IgE and the factors contributing to their generation, recruitment, and persistence. Skin samples from 30 patients with BP were stained to identify ASCs and the immunoglobulin type they expressed. The presence of tertiary lymphoid organ (TLO) elements, which generate ASCs in non-lymphoid tissues, and the chemokines CXCL12 and CXCL13, which regulate the migration/persistence of ASCs in lymphoid tissues and formation of TLOs, respectively, were evaluated in BP skin. BP skin harboured ASCs expressing the two types of antibodies IgG and IgE. ASCs were found in high-grade cellular aggregates containing TLO elements: T cells, B cells, CXCL12+ cells, CXCL13+ cells and high endothelial venules. IgG+ ASCs were detected among these aggregates, whereas IgE+ ASCs were dispersed throughout the dermis. CXCL12+ fibroblast-like cells were located close to ASCs. The inflammatory microenvironment of BP lesions may contribute to the antibody load characteristic of the skin of patients with BP by providing a site for the presence of ASCs. CXCL13 and CXCL12 expression may contribute to the generation and recruitment/survival of ASCs, respectively.
A pharmaceutical composition for an inhalable medicine using fibroblast growth factor-2 as an active ingredient is provided to ensure an excellent treatment effect with a little amount of the inhalable medicine without a side effect. A pharmaceutical composition for a chronic obstructive pulmonary disease comprises fibroblast growth factor-2 as an active ingredient. The fibroblast growth factor-2 is administered to patients who suffer from asthmas or chronic obstructive lung diseases with the amount of 0.015-600ng per day. The liquid composition is transferred to a lung by a nebulizer. The suspension composition is transferred to the lung through a metered dose inhaler. The powder composition is transferred to the lung through a dried powder inhaler.
Stonewall (oral dissolvable tobacco product). Dosage: 0.28-0.57 mg nicotine per portion.
Subjects will receive DNL747 for 29 days for the first period and then will switch to placebo for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods.
P2X7 receptor activation by extracellular adenosine triphosphate (eATP) modulates different intracellular pathways, including pro-inflammatory and tumor-promoting cascades. ATP is released by cells and necrotic tissues during stressful conditions and accumulates mainly in the inflammatory and tumoral microenvironments. As a consequence, both the P2X7 blockade and agonism have been proposed as therapeutic strategies in phlogosis and cancer. Nevertheless, most studies have been carried out on the WT fully functional receptor variant. In recent years, the discovery of P2X7 variants derived by alternative splicing mechanisms or single-nucleotide substitutions gave rise to the investigation of these new P2X7 variants' roles in different processes and diseases. Here, we provide an overview of the literature covering the function of human P2X7 splice variants and polymorphisms in diverse pathophysiological contexts, paying particular attention to their role in oncological and neuroinflammatory conditions.
Ocular complications are one of the rare side effects that can be seen after a mandibular nerve block and have the most dramatic results. Since the mandibular nerve block is mostly performed by dentists, this complication is mostly seen after an intraoral mandibular nerve block. The mandibular nerve is the third division of the trigeminal nerve. It is the most caudal and lateral part of Gasser's ganglion. It arises from the middle cranial fossa through the foramen ovale. In this region, a block method, which is performed by passing through the coronoid process, has been defined. This block, usually made using anatomical markers, is used in the treatment of trigeminal neuralgia. A 42-year-old female patient was admitted to our department for a maxillary and mandibular block with a diagnosis of trigeminal neuralgia. Immediately after the administration of the local anesthetic, the patient described a complete loss of vision. The complaint of vision loss lasted for about 1 minute, after which the patient's complaint of diplopia continued for 2 hours and 10 minutes. This case report presents the ocular complications after a mandibular block applied with the extraoral technique as an unexpected side effect.
The invention provides a gastric mucosa wound surface protective adhesive with thixotropy and acid sensitivity and application thereof, belonging to the field of biological medicine preparations. The stomach mucosa wound surface protective adhesive with thixotropy comprises the effective components of a tackifier, an acid-sensitive gelling substance, a thixotropic agent, a plasticizer, a retarder and a pH value regulator, wherein the pH value of the stomach injury mucosa wound surface protective adhesive is more than or equal to 7. The protective glue can be solidified at the designated position by further comprising a solidifying liquid. The protective glue can form a colloid film on the surface of the ulcer to promote the healing of the ulcer. In addition, the invention ensures that the product has thixotropy and can keep a non-flowing state on the wound surface in a short time, and then the curing liquid is adopted to ensure that the protective adhesive is quickly fixed on the surface of the damaged mucosa, thereby solving the flowing problem of the protective adhesive. Animal experiments show that the invention can obviously promote the repair of the injured gastric mucosa, thereby having the effects of promoting healing and protecting the injury of the gastric mucosa.
A dietary intervention that relies on the administration of 30 ml of sunflower oil per day for 6 months will be utilized in this study. The oil administered will replace the cooking/vegetable oil usually used by the participants.
BACKGROUND: Chromobacterium is a genus of fourteen species with validly published names, most often found in soil and waters in tropical and subtropical regions around the world. The most well-known species of the genus, C. violaceum, occasionally causes clinically relevant infections; cases of soft tissue infections with septicemia and fatal outcomes have been described.
CASE PRESENTATION: Here, we present a clinical case report of a 79-year-old man from Sweden with a soft-tissue infection and septicemia. The pathogen was identified as a strain of Chromobacterium species, but not C. violaceum. The patient was treated with clindamycin and ciprofloxacin and recovered well.
CONCLUSIONS: This case report demonstrates the potential of Chromobacterium species as infectious agents in immunocompetent patients. It also indicates the existence of a novel species.